2024
Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Thakkar D, Hill B, Kositsky R, Tian S, Biral L, Russell V, Dave T, Love C, Roth C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, McCall C, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Gordillo C, Just B, Cohen J, Baim A, Barbello J, Cavallone E, Bachanova V, Laschen M, Teferra A, Lorcy F, Lamure S, Cartron G, Dardalhon V, Naresh K, Czader M, Reddy A, Thacker E, Parker C, Happ L, Dave S. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL. Blood 2024, 144: 3409. DOI: 10.1182/blood-2024-199758.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T-cell-related encephalopathy syndromeProgression-free survivalCAR-T therapyDiffuse large B-cell lymphoma patientsActivated B-cell typeInternational Prognostic IndexChimeric antigen receptorCAR-TCytokine release syndromeOverall survivalFavorable prognosisPrognostic scoreB cellsAssociated with worse progression-free survivalAssociated with progression-free survivalSubtype of diffuse large B-cell lymphomaHigher International Prognostic IndexInternational Prognostic Index scoreAchievement of complete remissionLarge B-cell lymphomaTumors prior to treatmentSide effectsMultiple extranodal sitesSurface markers CD19
2021
Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
Hill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.Peer-Reviewed Original ResearchCAR T-cell therapyDiffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyLarge B-cell lymphomaT-cell therapyCAR-T therapyB-cell lymphomaInferior PFSR diseaseBristol-Meyers SquibbCurrent equity holderADC therapeuticsCell therapySpeakers bureauBristol-Myers SquibbKite PharmaDLBCL patientsTreatment outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyCD19 chimeric antigen receptor (CAR) T-cell therapyIntroduction Diffuse large B-cell lymphomaPre-treatment tumor biopsiesRelapsed/refractory (R/R) diseaseCAR T-cell infusionAdvisory Committee